language_icon
EN
HI

Eris Lifesciences Share price

ERIS

1343.8

42.10 (-3.04%)
NSE
BSE
Last updated on 22 May, 2026 | 15:30 IST
Today's High

1397.90

Today's Low

1341.10

52 Week Low

1200.00

52 Week High

1910.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Eris Lifesciences Chart

Eris Lifesciences Share Key Metrics

Volume
1.29 L
Market Cap
18617.39 CR
LTQ@LTP
73@1343.80
ATP
1357.07
Var Margin
16.67 %
Circuit Range
1108.8-1663
Delivery %
19.89 %
Value
17.57 CR
ASM/GSM
No
Market Lot
1

Summary

22 May, 2026 | 15:30 को, Eris Lifesciences का शेयर प्राइस आज ₹1343.8 पर है, जो दिन के लिए 42.10% की -3.04 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹1341.10 और ₹1397.90 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹1200.00 से ₹1910.00 तक रही है। ट्रेडिंग गतिविधि के मामले में, Eris Lifesciences ने 129472 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹138542887 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹135707 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 73,134380 रही। यह स्टॉक ₹1108.8-1663 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹17.57 CR है। दिन के लिए डिलीवरी परसेंटेज 19.89% रही। इसके अतिरिक्त, Eris Lifesciences वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Eris Lifesciences Fundamentals

View More
P/E Ratio

30.07

P/B Ratio

4.77

Div. Yield

0.54

Sector P/E

70.19

Sector P/B

3.46

Sec. Div. Yield

0.55

Eris Lifesciences Resistance and Support

Pivot 1429.4

Resistance

First Resistance

1486.5

Second Resistance

1587.1

Third Resistance

1644.2

Support

First Support

1328.8

Second Support

1271.7

Third Support

1171.1

Eris Lifesciences Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

53.92%

Mutual Fund

18.22%

Insurance

1.31%

Foreign Institutional Investors

6.39%

Domestic Institutional Investors

0.82%

Retail

19.33%

Others

0.01%

Total Promoters
MAR '26
53.92%

Eris Lifesciences Corporate Actions

DateAgenda
2026-05-20Audited Results & Interim Dividend
2026-02-13Quarterly Results

Eris Lifesciences News

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Eris Lifesciences has made available the recording of its earnings conference call for the Q4 and FY26 audited financial results. The call was held on May 20, 2026, and the recording is accessible on the company's website, providing investors with details on its financial performance.
May 20 2026 19:05:00

Eris Life Q4 Results: Stock gains 12% as Domestic Branded Formulations leads growth

Eris Lifesciences reported a 4% year-on-year decrease in Q4 FY24 net profit to ₹100 crore and a marginal dip in revenue to ₹447 crore. Despite the Q4 performance, the company has set ambitious targets, aiming for ₹2,500 crore in revenue for FY25 and a 35% margin by FY27, supported by the upcoming launch of Semaglutide pens and recent acquisitions in insulin and dermatology segments.
May 20 2026 15:05:00

Eris Lifesciences Ltd - 540596 - Corporate Action-Board approves Dividend

Eris Lifesciences declared an interim dividend of ₹7.21 per equity share for FY26-27. The record date for eligible shareholders is May 29, 2026, with payment due by June 19, 2026.
May 20 2026 14:05:00

Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for Outcome Of Board Meeting

Eris Lifesciences board approved audited cons. financial results for FY26, reporting a revenue of ₹3,129.42 cr and net profit of ₹647.51 cr. The company also declared an interim dividend of ₹7.21 per equity share for FY26-27, with payment scheduled by June 19, 2026.
May 20 2026 14:05:00

Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Consideration Of Financial Results And Interim Dividend

Eris Lifesciences board is scheduled to meet on May 20, 2026. The agenda includes approval of Q4 FY26 financial results and consideration of an interim dividend for FY27.
May 15 2026 14:05:00

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Credit Rating

India Ratings and Research affirmed Eris Lifesciences's Long-term Issuer Rating and bank facilities at 'IND AA' with a Stable outlook. This affirmation reflects sustained healthy operating performance and strong competitive position.
May 08 2026 17:05:00
Read More

About Eris Lifesciences AboutThe

NSE : 21154  
BSE : 540596  
ISIN : INE406M01024  

The Company was incorporated as “Eris Lifescience Private Limited” on January 25 2007 as a private limited company under the Companies Act 1956 at Ahmedabad with a certificate of incorporation granted by the Registrar of Companies Gujarat Dadra and Nagar Haveli. Pursuant to a resolution of the Shareholders dated February 5 2007 the name of the Company was changed to “Eris Lifesciences Private Limited” and a fresh certificate of incorporation was issued by the Registrar of Companies Gujarat Dadra and Nagar Haveli on February 9 2007. Further pursuant to a conversion of the Company to a public limited company and as approved by the Shareholders through a resolution dated January 31 2017 the name was changed to “Eris Lifesciences Limited” and the RoC issued a fresh certificate of incorporation on February 2 2017.Major events and milestonesThe table below sets forth some of the major events in the history of the Company.2007-Incorporation of the Company-Launched “Eris” division focused on cardiology and diabetes segment2008-Launched “Nikkos” division focused on gastroenterology and orthopedics segment2009-Launched “Adura” division focused on cardiology and diabetes segment2011-Launched “Montana” division focused on gynecology and pediatrics segment2012-Launched “Inspira” division focused on cardiology segment2014-Launched “Victus” division focused on anti-diabetes segment-Set up Assam Facility by the Company2015-Launched “Eris 2” division focused on pain management segment2016-Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now Aprica Pharmaceuticals Private Limited)-Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited-Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited2017-Acquired the trademarks ‘UNION’ ‘REUNION’ and ‘BON UNION’Awards and Accreditations :2013-Awarded ‘Competitive Strategy Leadership’ award by Frost & Sullivan-Awarded ‘Emerging Companies Excellence’ award for scalability of business model and managing operational efficiencies by Business Today and Yes Bank

Read More

Eris Lifesciences Management

NamePosition
Milind TalegaonkarCompany Secretary & Compliance Officer
Krishnakumar VaidyanathanWhole Time Director & COO
View More

Eris Lifesciences FAQs

Eris Lifesciences शेयर का खरीद मूल्य 1343.8 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Eris Lifesciences शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Eris Lifesciences शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 30.07 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Eris Lifesciences शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 4.77 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Eris Lifesciences शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 3.46 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Eris Lifesciences का मार्केट कैप 18617.39 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Eris Lifesciences शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 1910.00 और 1200.00 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost